Description

Antiviral agent. It specifically inhibits in vitro influenza A and B viruses (Influenzavirus A, B), including highly pathogenic subtypes A (H1N1) pdm09 and A (H5N1), as well as other viruses that cause acute respiratory viral infections (Coronavirus) associated with severe acute respiratory syndrome ( SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus)). The mechanism of antiviral action refers to fusion inhibitors (fusions), interacts with the hemagglutinin of the virus and prevents the fusion of the lipid envelope of the virus and cell membranes. It has interferon-inducing activity – in a study on mice, the induction of interferons was observed already after 16 hours, and high titers of interferons remained in the blood for up to 48 hours after administration. Stimulates cellular and humoral immunity reactions: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helper cells (CD4), without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer cells (NK cells).
Therapeutic efficacy in viral infections manifests itself in reducing the duration and severity of the disease and its main symptoms, as well as reducing the incidence of complications associated with viral infection and exacerbations of chronic bacterial diseases.
Treats low-toxic drugs (LD50> 4 g / kg). It does not have any negative effects on the human body when taken orally at recommended doses.
Pharmacokinetics. Rapidly absorbed and distributed to organs and tissues. The maximum concentration in the blood plasma when taking the drug in a dose of 200 mg of umiphenovir is reached after 1 hour, the volume of distribution (Vd) – 1432 l. Metabolized in the liver. The average half-life averages 11 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and, in small amounts, by the kidneys (0.12%). During the first day, 90% of the injected dose is eliminated.